Improved calcification resistance and biocompatibility of tissue patch grafted with sulfonated PEO or heparin after glutaraldehyde fixation.
A novel chemical modification of biological tissues was developed aimed at improving biocompatibility and calcification resistance. This method involved the additional grafting of sulfonated PEO (PEO-SO(3)) or heparin after conventional glutaraldehyde (GA) fixation of bovine pericardium (BP). The amino groups of PEO-SO(3) or heparin were utilized to react to the GA residues to block them. The PEO-SO(3) or heparin grafted tissues demonstrated a slightly higher shrinkage temperature and tensile strength, but greater resistance to collagenase digestion, than GA treated ones. These results suggest that modified tissues have improved durability due to the grafting and filling effect of PEO-SO(3) or heparin in addition to the GA cross-linking. At the direct contact cytotoxicity test in vitro, PEO-SO(3) or heparin grafted tissue was shown to be nontoxic, while relatively significant cytotoxicity was observed for the GA treated tissues, possibly due to the release of GA. From the in vivo calcification study, calcium contents deposited on the modified tissues were much less than those on GA treated tissues. Such a decreased calcification might be explained by the decrease of residual GA groups during the additional treatment, and the space-filling effect and the nonadhesive property and/or the blood compatibility of PEO-SO(3) or heparin grafted covalently. The newly modified tissue patch was observed to show improved pathological assessibility including less inflammation and tissue reactions. This simple modification method may be useful for calcification-resistant and blood-compatible tissue patches for cardiovascular implants.
Lee
W K
WK
Korea Institute of Science and Technology, Biomaterials Research Center, P.O. Box 131, Cheongnyang, Seoul 130-650, Korea.
Park
K D
KD
Kim
Y H
YH
Suh
H
H
Park
J C
JC
Lee
J E
JE
Sun
K
K
Baek
M J
MJ
Kim
H M
HM
Kim
S H
SH
D000818:Animals; D001013:Aorta, Thoracic / Q000473:pathology / Q000601:surgery; D001672:Biocompatible Materials / Q000737:chemistry / Q000633:toxicity; D001705:Bioprosthesis; D001894:Borohydrides / Q000494:pharmacology; D002114:Calcinosis / Q000517:prevention & control*; D002417:Cattle; D017364:Collagenases / Q000494:pharmacology; D003432:Cross-Linking Reagents / Q000737:chemistry / Q000494:pharmacology* / Q000633:toxicity; D062109:Dermatologic Surgical Procedures; D004285:Dogs; D005404:Fixatives / Q000737:chemistry / Q000494:pharmacology* / Q000633:toxicity; D005976:Glutaral / Q000737:chemistry / Q000494:pharmacology* / Q000633:toxicity; D006493:Heparin / Q000737:chemistry / Q000494:pharmacology* / Q000633:toxicity; D007739:L Cells / Q000187:drug effects; D008297:Male; D008422:Materials Testing; D051379:Mice; D010084:Oxidation-Reduction; D010496:Pericardium / Q000737:chemistry / Q000187:drug effects*; D011092:Polyethylene Glycols / Q000737:chemistry / Q000494:pharmacology*; D011651:Pulmonary Artery / Q000473:pathology / Q000601:surgery; D051381:Rats; D017207:Rats, Sprague-Dawley; D012867:Skin / Q000473:pathology; D013048:Specimen Handling; D013451:Sulfonic Acids / Q000737:chemistry / Q000494:pharmacology*; D013696:Temperature; D013718:Tensile Strength
D001672:Biocompatible Materials; D001894:Borohydrides; D003432:Cross-Linking Reagents; D005404:Fixatives; D013451:Sulfonic Acids; C426021:amino-polyethyleneoxide-sulfonate; D011092:Polyethylene Glycols; C025364:sodium borohydride; D006493:Heparin; D017364:Collagenases; D005976:Glutaral